Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 179 participants.

Also called NCT01687491

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 179 participants (enrolled count) (from the registry)
Sponsor
Les Laboratoires des Médicaments Stériles (from the registry)
Registry
  • NCT NCT01687491
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Tunisia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01687491. Randomized; single masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Anti-Xa Activity of ENOXA ® Versus LOVENOX ® in Acute Coronary Syndrome
Acronym
AXA
Condition
Acute Coronary Syndrome
Condition
Factor X
Intervention (Drug)
ENOXA®
Intervention (Drug)
LOVENOX®
Lead sponsor
Les Laboratoires des Médicaments Stériles (class: industry)
Collaborator
University Hospital Fattouma Bourguiba (class: other)

Record details

Record id
cardio:ct-nct01687491
Content hash
954e2fb97d21acc44bd869629056bdef8ca13aefa01214e2c81a6c11ef38a090